U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 541 - 550 of 33407 results

Status:
Investigational
Source:
INN:carbocloral [INN]
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Carbocloral is a carbamate ester derivative used as sedative and hypnotic drug. Carbocloral is as effective as chloral hydrate in producing sedation, hypnosis, and general anesthesia, and more effective in inducing relaxation of skeletal muscles. Carbocloral was also more effective as an anticonvulsant and less toxic than chloral hydrate.
Status:
Investigational
Source:
INN:sulfogaiacol [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Potassium guaiacolsulfonate also known as sulfoguaiacolum is a salt of GUAIACOLSULFONIC ACID, which is used as an expectorant, to relieve symptoms of cough and mucus in the chest due to respiratory infections, asthma, colds, or hay fever. It works by thinning mucus (phlegm) in the lungs, making it less sticky and easier to cough up. This reduces chest congestion by making coughs more productive.
Status:
Investigational
Source:
INN:olpadronic acid
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Olpadronate, a nitrogenated bisphosphonate that can inhibit bone resorption. Although it shares the therapeutic and pharmacological properties of pamidronate and alendronate, it has a greater dosage amplitude, more predictable effects, and greater digestive tolerability than other bisphosphates. Clinical trials have shown that the oral olpadronate was well tolerated and effective in the treatment of Paget's disease. In addition, the drug is ongoing in phase II clinical trials in the Netherlands. This clinical trial has to assess the efficacy of the intravenous drug in decreasing the average back pain intensity from baseline.
Status:
Investigational
Source:
INN:darodipine
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Darodipine is a calcium channel blocking drug, developed by Sandoz in the early 1980s. It potently and selectively antagonizes calcium-induced contraction, decreases the rate of spontaneously beating guinea-pig and rabbit atria. In open-chest dogs, darodipine increased coronary flow and cardiac output, lowered blood pressure, and tended to decrease heart rate while the myocardial contractile force was unchanged. Administration of darodipine led to a significant reduction in mortality and in the severity of neurological symptoms in various types of experimental brain ischemia. Clinical trials demonstrated efficacy for the treatment of stable angina pectoris. In the pilot trial, darodipine was found to be safe but not effective in patients with acute ischemic cerebral infarction.
Status:
Investigational
Source:
INN:cevoglitazar [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Cevoglitazar is a dual agonist for the peroxisome proliferator-activated receptor (PPAR)-alpha and -gamma subtypes. Cevoglitazar was as effective as pioglitazone at improving glucose tolerance, normalizes intramyocellular lipids and reduces body weight gain and adiposity, independent of food intake. Metabolic profiling showed that in the muscle cevoglitazar improves the lipid profile via both PPARα‐ and PPARγ‐mediated mechanisms. Cevoglitazar only induced small changes to the lipid composition of visceral fat. In subcutaneous fat, however, cevoglitazar induced changes similar to those observed with fenofibrate suggesting export of fatty acids from this depot.
Status:
Investigational
Source:
INN:lepzacitinib [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:tioxaprofen
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)


An oxazole compound, tioxaprofen, exerted a strong anti-mycotic activity against Trichophyton mentagrophytes and T. rubrum, which were major dermatophytes from patients. It was found that tioxaprofen was a potent uncoupling agent of mitochondrial respiration. Tioxaprofen inhibits the electron transport between cytochromes b and c1 in the mitochondrial respiratory chain. Tioxaprofen blocks the formation of thromboxane most probably by inhibition of cyclo-oxygenase.
Status:
Investigational
Source:
INN:myfadol
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Myfadol is a phenacylpiperidine derivative patented by Tanabe Seiyaku Co., Ltd as low molecular weight non-peptide analgesic. Myfadol produces hot-plate analgesia in rodents with minimal side-effects, and when given parenterally in humans produces analgesia to experimentally-produced and postoperative pain.
Status:
Investigational
Source:
INN:remiprostol [INN]
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Remiprostol (also known as SC-46275) is a potent, long-acting gastric antisecretory agent that is not readily available systemically after oral administration. This prostaglandin analog is a very potent and highly selective EP3 receptor agonist with antisecretory and cytoprotective actions. Remiprostol was suggested to be potentially useful in the therapeutic treatment of inflammatory diseases such as peptic ulcer disease (painful sores or ulcers in the stomach or small intestine), ulcerative colitis, Crohn's disease, and autoimmune inflammatory diseases of the central nervous system.